Video

Dr. Berenson on the Study of Zometa in Multiple Myeloma

Author(s):

James R. Berenson, MD

James R. Berenson, MD, Medical & Scientific Director; Institute for Myeloma & Bone Cancer Research, on a study of zoledronic acid (Zometa) in patients with multiple myeloma.

James R. Berenson, MD, Medical & Scientific Director; Institute for Myeloma & Bone Cancer Research, on a study of zoledronic acid (Zometa) in patients with multiple myeloma.

Related Videos
Fred Saad, CQ, MD, FRCS, FCAHS
Ajai Chari, MD
Lillian L. Siu, MD, FRCPC
Marc Machaalani, MD
Mark Awad, MD, PhD, chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Rasha Cosman, BSc, MBBS, FRACP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Nicholas P. McAndrew, MD, MSCE
Xichun Hu, MD, PhD
Nicolas Girard, MD
Related Content
Steven A. Shallcross
October 3rd 2024

Ribaxamase Shows Safety in the Prevention of aGVHD Following Allo-HSCT

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Multiple Myeloma Image Credit: © Dr_Microbe - stock.adobe.com
October 2nd 2024

Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Surbhi Sidana, MD
October 1st 2024

Cilta-Cel Shows Real-World Feasibility and Efficacy With Acceptable Safety in R/R Myeloma

María-Victoria Mateos, MD, PhD
October 1st 2024

Cilta-Cel Prolongs OS in Lenalidomide-Refractory Multiple Myeloma